SCHEMBL329461

SCHEMBL329461

O=S(=O)(O)C1CCCCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
CYP3A4 P08684 2/20 0.55
LMNA P02545 1/20 0.55
GABRA1 P14867 1/20 0.55
GABRG2 P18507 1/20 0.55
NFKB1 P19838 1/20 0.55
GABRB3 P28472 1/20 0.55
GABRA5 P31644 1/20 0.55
GABRA3 P34903 1/20 0.55
GABRA2 P47869 1/20 0.55
GABRA6 Q16445 1/20 0.55
EPHX2 P34913 3/20 0.38
CA1 P00915 3/20 0.38
CA12 O43570 2/20 0.38
CA7 P43166 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
EPHX1 P07099 6/20 0.35
CA2 P00918 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10012314 1.00 TSHR (0.55) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL17022282 1.00 TSHR (0.55) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL15586623 1.00 TSHR (0.55) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL3004 1.00 TSHR (0.55) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL2024638 1.00 TSHR (0.55) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL329394 1.00 TSHR (0.55) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL7097318 0.97 TSHR (0.52) TSHRCYP3A4LMNAGABRA1GABRG2
Hydrochloric Acid SCHEMBL11523265 0.97 TSHR (0.52) TSHRCYP3A4LMNAGABRA1GABRG2
Fluoride SCHEMBL11751487 0.97 TSHR (0.52) TSHRCYP3A4LMNAGABRA1GABRG2
SCHEMBL11696325 0.97 TSHR (0.52) TSHRCYP3A4LMNAGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4366733-A1 TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF LANDOS BIOPHARMA, INC. (US) 2024-05-15 EP disclosed
CN-117835980-A Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof 朗多生物制药股份有限公司 2024-04-05 CN disclosed
EP-3927427-B1 LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME NIMMUNE BIOPHARMA INC (US) 2024-02-07 EP disclosed
US-20230357744-A1 ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2023-11-09 US disclosed
EP-4225315-A2 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES Nimmune Biopharma, Inc. (US) 2023-08-16 EP disclosed
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
WO-2023141301-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. (US) 2023-07-27 WO disclosed
EP-4214200-A1 LANCL LIGANDS Nimmune Biopharma, Inc. (US) 2023-07-26 EP disclosed
CN-113748109-B Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands 朗多生物制药股份有限公司 2023-07-21 CN disclosed
EP-1932839-A1 INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY Shionogi Co., Ltd. (JP) 2008-06-18 EP disclosed
EP-1916245-A1 INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY Shionogi Co., Ltd. (JP) 2008-04-30 EP disclosed
EP-1911759-A1 AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY Shionogi Co., Ltd. (JP) 2008-04-16 EP disclosed
CN-1678315-A Prodrugs of imidazole derivatives as proton pump inhibitors for the treatment of e.g. peptic ulcers TAKEDA PHARMACEUTICAL (JP) 2005-10-05 CN disclosed
US-6706915-B2 USING A METAL COMPOUND AS A CATALYST, A CORRESPONDING ORGANIC SULFONIC ACID OR A SALT CAN BE OBTAINED BY REACTING AN ORGANIC SUBSTRATE WITH A SULFUR OXIDE IN THE ABSENCE OF N-HYDROXY AND N-OXO CYCLIC IMIDE COMPOUNDS DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-16 US disclosed
EP-1036788-B1 Process for producing sulfonic acids or salts thereof DAICEL CHEM (JP) 2003-06-04 EP disclosed
US-20020161255-A1 Process for preparing organic sulfur acids or salts thereof DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2002-10-31 US disclosed
EP-1188743-A1 PROCESS FOR PREPARING ORGANIC SULFUR ACIDS OR SALTS THEREOF Daicel Chemical Industries, Ltd. (JP) 2002-03-20 EP disclosed
US-6143924-A Process for producing organic sulfur acids or salts thereof DAICEL CHEMICAL INDUSTRIES, LTD (JP) 2000-11-07 US disclosed
EP-1036788-A1 Process for producing sulfonic acids or salts thereof Daicel Chemical Industries, Ltd. (JP) 2000-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161255-A1 Process for preparing organic sulfur acids or salts thereof BHMT2, TST, ICMT TSHR 4312/4885CYP3A4 753/4885LMNA 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.